Xiao Zhang

Xiao Zhang

Auto-generated profile, based on publicly available information

Xiao Zhang

Department of Radiology, West China Hospital, Sichuan University, Chengdu, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
DLDan Liu
Dan Liu
WZWeihan Zhang
Weihan Zhang
FHFubi Hu
Fubi Hu
PYPengxin Yu
Pengxin Yu
XZXiao Zhang
Xiao Zhang
ZHZixing Huang
Zixing Huang
Purpose: To develop a bounding box (BBOX)-based radiomics model for the preoperative diagnosis of occult peritoneal metastasis (OPM) in advanced gastric cancer (AGC) patients.Materials and Methods: 599 AGC patients from 3 centers were retrospectively enrolled and were divided into training, validation, and testing cohorts. The minimum circumscribed rectangle of the ROIs for the largest tumor area (R_BBOX), the nonoverlapping area between the tumor and R_BBOX (peritumoral area; PERI) and the smallest rectangle that could completely contain the tumor determined by a radiologist (M_BBOX) were used as inputs to extract radiomic features. Multivariate logistic regression was used to construct a radiomics model to estimate the preoperative probability of OPM in AGC patients.Results: The M_BBOX model was not significantly different from R_BBOX in the validation cohort [AUC: M_BBOX model 0.871 (95% CI, 0.814–0.940) vs. R_BBOX model 0.873 (95% CI, 0.820–0.940); p = 0.937]. M_BBOX was selected as the final radiomics model because of its extremely low annotation cost and superior OPM discrimination performance (sensitivity of 85.7% and specificity of 82.8%) over the clinical model, and this radiomics model showed comparable diagnostic efficacy in the testing cohort.Conclusions: The BBOX-based radiomics could serve as a simpler reliable and powerful tool for the preoperative diagnosis of OPM in AGC patients. And M_BBOX-based radiomics is simpler and less time consuming.

8 March 2021 in Cardiology in the Young
Verified
Journal Article
Closed access
PDF file
YLYunxia Lei
Yunxia Lei
XZXiao Zhang
Xiao Zhang
YFYuan Feng
Yuan Feng
JWJieying Wang
Jieying Wang
RLRiqiang Luo
Riqiang Luo
Objectives: Pulmonary arterial hypertension symptoms in systemic lupus erythematosus patients are non-specific and early diagnosis and intervention are challenging. It remains essential to explore risk factors for pulmonary arterial hypertension in systemic lupus erythematosus patients to identify high risk patients and allow intensive monitoring.Methods: From January 2010 to December 2018, 84 patients with systemic lupus erythematosus and pulmonary arterial hypertension and 160 patients with systemic lupus erythematosus but without pulmonary arterial hypertension were enrolled. Clinical manifestations and laboratory test results were compared between the two groups to identify predictors of pulmonary arterial hypertension. Candidate pulmonary arterial hypertension risk factors were further compared among systemic lupus erythematosus-pulmonary arterial hypertension patients with different characteristics.Results: Among collected patient characteristics, Raynaud’s phenomenon (OR 2.32, 95% CI: 1.17–4.61), digital vasculitis (OR 4.12, 95% CI: 1.48–11.49), pericardial effusion, pulmonary interstitial lesions, positive anti-u1 ribonucleoprotein antibodies, and positive anticardiolipin antibodies immunoglobulin G were associated with significantly higher risk of pulmonary arterial hypertension in systemic lupus erythematosus patients. Among these candidate risk factors, positive anti-u1 ribonucleoprotein antibody was independently associated with severe pulmonary arterial hypertension and more active disease. Digital vasculitis was independently associated with systemic lupus erythematosus alleviation, while pericardial effusion was associated with systemic lupus erythematosus deterioration. Pericardial effusion was associated with longer pulmonary arterial hypertension duration.Conclusion: The significant association between studied clinical and laboratory indicators and risk of pulmonary arterial hypertension, pulmonary arterial hypertension and systemic lupus erythematosus characteristics suggested that these factors can be used to identify patients at higher risk of pulmonary arterial hypertension and adverse outcomes. Close monitoring may be indicated in patients with these risk factors, especially with more than one risk factor.

29 July 2020 in Research Square
Verified
Preprint
Open access
PDF file
YLYunxia Lei
Yunxia Lei
XZXiao Zhang
Xiao Zhang
YFYuan Feng
Yuan Feng
JWJieying Wang
Jieying Wang
RLRiqiang Luo
Riqiang Luo
Introduction : Pulmonary arterial hypertension (PAH) symptoms in systemic lupus erythematosus (SLE) patients are non-specific and early diagnosis and intervention are challenging. It remains essential to explore risk factors for PAH in SLE patients to identify high risk patients and allow intensive monitoring. Methods From January 2010 to December 2018, 84 patients with SLE and PAH and 160 patients with SLE but without PAH were enrolled. Clinical manifestations and laboratory test results were compared between the two groups to identify predictors of PAH. Candidate PAH risk factors were further compared among SLE-PAH patients with different characteristics. Results Among collected patient characteristics, Raynaud's phenomenon (OR 2.32, 95% CI: 1.17–4.61), digital vasculitis (OR 4.12, 95% CI: 1.48–11.49), pericardial effusion, pulmonary interstitial lesions, positive anti-U1RNP antibodies, and positive ACA-IgG were associated with significantly higher risk of PAH in SLE patients. Among these candidate risk factors, positive anti-U1RNP antibody was independently associated with severe PAH and more active disease. Digital vasculitis was independently associated with SLE alleviation, while pericardial effusion was associated with SLE deterioration. Pericardial effusion was associated with longer PAH duration. Discussion The significant association between studied clinical and laboratory indicators and risk of PAH, PAH and SLE characteristics suggested that these factors can be used to identify patients at higher risk of PAH and adverse outcomes. Close monitoring may be indicated in patients with these risk factors, especially with more than one risk factor.